Literature DB >> 6944425

Effects of prior therapy on plasma levels of adriamycin during subsequent therapy.

T Gessner, J Robert, W Bolanowska, B Hoerni, M Durand, H Preisler, J Rustum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6944425

Source DB:  PubMed          Journal:  J Med        ISSN： 0025-7850


× No keyword cloud information.
  10 in total

1.  Pharmacokinetic study of i.v. infusions of adriamycin.

Authors:  S Eksborg; H S Strandler; F Edsmyr; I Näslund; P Tahvanainen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia.

Authors:  H D Preisler; T Gessner; N Azarnia; W Bolanowska; J Epstein; A P Early; P D'Arrigo; R Vogler; L Winton; P Chervenik
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Authors:  J Robert; B Hoerni; P Vrignaud; C Lagarde
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Disposition of epirubicin and metabolites with repeated courses to cancer patients.

Authors:  R G Morris; D Kotasek; G Paltridge
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.

Authors:  C J Twelves; N A Dobbs; M Aldhous; P G Harper; R D Rubens; M A Richards
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Time dependency of adriamycin and adriamycinol kinetics.

Authors:  P Gil; R Favre; A Durand; A Iliadis; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Authors:  L Simpson-Herren; P E Noker; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.

Authors:  J Cummings; G J Forrest; D Cunningham; N L Gilchrist; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.